Floatz logo

Midazolam

Gastrointestinal Stromal Tumor

Blueprint Medicines CorporationSmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Gastrointestinal Stromal Tumor cohort.

Asset / SponsorPhaseRating
Regorafenib
Institut Bergonié
Phase 4BBB
Esomeprazole
Erasmus Medical Center
Phase 4BB
CAFFEINE
Markus Joerger
Phase 4BB
Imatinib
M.D. Anderson Cancer Center
Phase 2BB
Avapritinib
Blueprint Medicines Corporation
Phase 3BB

View all 49 →

Same molecule, other indications

Midazolam is also rated in:

neuralgiaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
choledocholithiasisActive
BBB
Indicative · Phase 4
73 / 100
View asset →
type 2 diabetes mellitusActive
BBB
Indicative · Phase 4
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →